Dean Eliott, MD
Ophthalmology · Boston, MANPI 1306883897
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $222,690 of the $249,966 with a category attached, or 89.1%. 19 manufacturers reported payments, led by Alcon at 52.8% of the total. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $1436.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$132K
- Alcon Research LLC$39K
- Genentech USA, Inc.$19K
- Dutch Ophthalmic, USA$16K
- Glaukos Corporation$12K
- AbbVie$10K
- plus $20K from 13 others
What the payments were for
- Consulting fees$222,69089%
- Speaking & faculty fees$9,9584%
- Travel & lodging$8,7063%
- Food & beverage$8,6123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 82 | $132,104 |
| Alcon Research LLC | 10 | $39,450 |
| Genentech USA, Inc. | 19 | $19,395 |
| Dutch Ophthalmic, USA | 7 | $16,250 |
| Glaukos Corporation | 7 | $12,222 |
| AbbVie(2 entities) | 18 | $10,153 |
| Apellis Pharmaceuticals, Inc. | 7 | $7,555 |
| Neurotech Pharmaceuticals, Inc. | 3 | $4,733 |
| Ocular Therapeutix, Inc. | 1 | $4,298 |
| Astellas Pharma US Inc | 1 | $2,600 |
| Regeneron | 3 | $384 |
| Genentech, Inc. | 7 | $262 |
| Regeneron Healthcare Solutions, Inc. | 1 | $127 |
| Eyepoint US, Inc. | 1 | $114 |
| Alimera Sciences, Inc. | 2 | $105 |
| Novartis | 2 | $87 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Dompe US, Inc. | 1 | $41 |
| Oculus Surgical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$93,553
- NGENUITY$51,175
- Unity$25,939
- Lucentis$13,638
- Alcon Greishaber Finesse$11,514
- EVA Ophthalmic Surgical System$11,375
- Luxor$11,200
- OZURDEX$9,051
- Systane$7,000
- LenSx$7,000
- ILUX$7,000
- Clareon$7,000
- SUSVIMO$5,432
- EVA, combined machine$4,875
- ENCELTO$3,743
- Centurion$3,150
- Syfovre$2,982
- Izervay$2,600
- TISSUEBLUE$2,250
- FINESSE SHARKSKIN$925
How this compares
$249,966 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 15 | $462 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
- Michael RaizmanBoston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.